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Bilateral simultaneous anterior ischemic optic neuropathy,
an extrahepatic manifestation of hepatitis C cured with
direct acting antivirals
Abstract
We report a patient with a bilateral optic anterior ischemic neuropathy
as an extrahepatic complication of a chronic hepatitis C (HCV) infection.
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The patient presented with a bilateral visual acuity loss and bilateral
Ingele Casteels1optic disc oedema. The optic neuropathy was associated with a sudden
increase in the viral HCV load after a recent liver transplantation. The
stop of the calcineurin inhibitor had no effect on the course of the optic 1 Division of Ophthalmology,
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neuropathy. Visual improvement and normalization of HCV viraemia
occurred after treatment with sofosbuvir and daclatasvir, which are
direct acting antivirals.
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Introduction
Chronic hepatitis C virus (HCV) infection is a global epi-
demic affecting almost 185 million people worldwide,
with an estimated 3–4 million new infections every year
[1]. HCV infection can lead to the development of liver
cirrhosis, hepatocellular carcinoma and liver failure [2].
HCV exhibits an extraordinarily high degree of genetic di-
versity. HCV genotype 1 is the most prevalent worldwide
[3]. Several extrahepatic manifestations of HCV have
been described such as cryoglobulinemia induced vascu-
litis [4], [5] and a possible relationship with non-arteritic
anterior ischemic neuropathy (NAION) [6].
Case report
A 68-year-old man was referred to our hospital with a
deteriorated general condition due to chronic hepatitis C
genotype 1b. In this advanced stage of disease, treatment
with pegylated interferon, ribavirin and a direct acting
antiviral (DAA) was not indicated. Progressive cirrhosis
necessitated a liver transplant 2 years later. The pre-
transplant ophtalmological examination was performed
6months before the actual liver transplantation and was
completely normal. Following the transplantation, treat-
ment with triple immunosuppression with tacrolimus,
mycophenolatic mofetil and prednisolone was initiated.
Tacrolimus was replaced by cyclosporine because of
confusion. Three months later, the liver function had
normalized with therapeutic blood levels of cyclosporine
around 75 µg/l, the viral load at that moment was
130,499 IU/ml. Four months after the liver transplanta-
tion, the patient developed an acute visual loss in both
eyes. Best-corrected visual acuity was 0.6 in the right eye
and 0.12 in the left eye. There was a relative afferent
pupillary defect in the right eye. On fundoscopy, bilateral
optic disc oedema with haemorrhages at the disc margin
was seen (Figure 1). Treatment with cyclosporine A was
interrupted and the dose of prednisolone was increased
to 24mg in combination withmycoplenolatic mofetil. One
month later his vision was at 0.4 in the right eye and 0.25
in the left eye. The papillary oedema gradually subsided
and the optic nerves became pale. Goldmann perimetry
showed normal peripheral limits and central visual field
testing showed a superior nasal scotoma in the right eye
and an inferior nasal scotoma in the left eye. Brain MRI
(magnetic resonance imaging) was within normal limits.
A blood sample could not detect any infectious causes
of an optic neuropathy, but an HCV viral load was
>5 million IU/ml was measured. Patient was closely
monitored, but after one month there was no visual im-
provement and optic pallor was progressive bilaterally;
the dosage of prednisolone was increased to 2 x 32 mg.
Six months after transplantation liver function tests de-
teriorated and the patient developed a histologically
proven fibrotic cholestatic hepatitis. Antiviral therapy with
peginterferon alpha 2a and ribavirin was given for one
month. During that month BCVA slightly decreased and
visual fields deteriorated. After this month, sevenmonths
after the liver transplant, therapy was switched to ribavirin
and sofosbuvir. Afterwards visual acuity stabilized and
Goldmann perimetry showed a scotoma inferior and
nasal in the right eye and a narrowing of the peripheral
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Figure 1: Papillary oedema at the begining in A) the right eye and B) the left eye
Figure 2: Atrophic optic nerve at the end of treatment in A) the right eye and B) the left eye
field in the left eye. Central visual field examination
showed an increase of the inferior nasal scotoma in both
eyes. Ten months after the transplant, therapy was
switched to daclatasvir and sofosbuvir because of the
availability of DAA (direct acting antiviral) in Belgium.
Prednisolone was progressively tapered and cyclosporine
was reintroduced. The viral load dropped to 373 IU/ml.
Over the following months, vision improved slightly to 0.7
in the right eye and to 0.5 in the left eye. The peripheral
and central visual fields improved. The optic nerves had
become atrophic (Figure 2). Liver function test normalized
and the viral load became undetectable. Three months
after the start of daclatasvir and sofosbuvir the patient
was a sustained responder and the liver test was com-
pletely normal.
Discussion
We report a patient with bilateral NAION in a patient with
a chronic hepatitis C infection. We assume a relationship
between the NAION and HCV, since he had a high viral
load (>5 million IU/ml) during the NAION. Treatment with
direct acting antivirals resulted in improvement of visual
acuity and of the fibrotic cholestatic hepatitis. We do not
believe this is a cyclosporin-induced NAION, since stop-
ping this medication had no effect on the visual acuity.
Fodo et al. reported a case of a consecutive bilateral
NAION presumably caused by hepatitis C virus type 1b
[6]. The patient developed an NAION in both eyes with a
time interval of fivemonths. Viral load was very high when
the contralateral NAION developed, as it was in our pa-
tient. Brain MRI was found to be normal. The patient was
treated with pegylated interferon and ribavirin. No further
deterioration occurred when antiviral therapy was started.
The association between a bilateral optic neuropathy and
a hepatitis C infection has been described before by
Siddiqui et al. [7]. Optic neuropathy emerged 2 weeks
after an acute hepatitis C infection. Vision recovered
completely after treatment with steroids. Optic neuropathy
in patients with hepatitis A and B [8], [9], [10] has also
been described 2 months after an episode of acute
hepatitis. In most patients treatment with steroids was
successful.
Optic neuropathy following the use of cyclosporine has
been linked in patients with a T-cell lymphoma [11]. Here,
a marked improvement of the vision and the visual field
was noted once cyclosporine was stopped.
Until recently treatment for chronic hepatitis C infection
consisted of pegylated interferon alpha and ribavirin. One
of the most frequent complications is an interferon-asso-
ciated retinopathy [12], [13]. This retinopathy occurs in
30–60% of cases. Since interferon was only given for a
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short period of time some months after the start of the
NAION, we don’t believe this medication had an effect on
the course of the visual symptoms.
At present, DAAs that do not require pegylated interferon
provide new opportunities for treatment of HCV. They
target specific steps within the HCV life cycle. A combin-
ation of these DAAs without pegylated interferon with a
treatment duration of 12–24 weeks offers a sustained
response rate in genotype 1b patients of >90% without
any significant adverse events even after liver transplant-
ation [14], [15]. In our case we show that these drugs
are also successful for the HCV induced fibrotic cholestat-
ic hepatitis seen after liver transplantation, which is a
life-threatening condition without antiviral treatment.
Conclusions
In conclusion, we report a case of bilateral optic NAION
witch is presumably an extrahepatic complication of a
chronic hepatitis C infection. One case has been reported
in literature [6]. In our patient, we can assume that a re-
activation of a chronic hepatitis C after liver transplanta-
tion was the triggering factor for the NAION, whereas in
the other case it was an HCV infection that had not been
treated before [6]. It is less likely that the cyclosporine
was responsible for this, since ceasing them had no effect
on the course.
In our patient the viral load was very high
(>5 million IU/ml) during the NAION; viral load was not
this high before. Vision stabilised and even improved after
starting DAA. This is also the moment when the viral load
started to decline and eventually became undetectable.
In our case we see correlation between the viral load and
the start of the visual deterioration of the patient. This is
the second case report where a correlation between the
development of an NAION and HCV can be assumed. Our
case is the first case where you can see improvement in
vision when the viral load dropped after a DAA was star-
ted.
Many other patients with HCV receive pegylated interferon
treatment, which is responsible for a lot of visual side
effects, but this is not the case in our patient since he
did not receive this therapy.
This case also illustrates again the efficacy of the combin-
ation of DAAs in the eradication of a chronic hepatitis C
infection in liver transplant patients suffering from
fibrotic cholestatic hepatitis.
In conclusion this case seems to show that NAION can
be caused by the virus itself and not only as a complica-
tion of the used therapy. In this case, targeting the cause
of the NAION prevented further deterioration.
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